Fenebrutinib: Roche reports smaller chronic MRI lesions in Phase 3 trials
Roche reported a late-breaking MRI analysis of its Phase 3 fenebrutinib trials at MSToronto2026, presented on 23 October 2026. It looked at slowly expanding lesions and paramagnetic rim lesions, MRI signs linked to chronic inflammation in the brain. Roche reported that the volume of slowly expanding lesions was up to 30% lower than with the comparison drug, in relapsing multiple sclerosis (MS) over 96 weeks and in primary progressive MS over 120 weeks. It also reported 62% less accumulation of paramagnetic rim lesions in relapsing MS. MS Australia's meeting summary gives lesion-volume reductions of 30.5% against teriflunomide in relapsing MS and 27.5% against ocrelizumab in primary progressive MS, and says the difference in new rim lesions was statistically significant in relapsing MS but not in primary progressive MS. In a separate pooled analysis of the relapsing MS trials, Roche reported a 55% lower annualised relapse rate than teriflunomide over 96 weeks, 23% less yearly brain volume loss, and a 16% reduction in 12-week composite confirmed disability progression.
Source: Roche — official company announcement ↗Source: MS Australia — research updates from MSToronto2026 ↗ Source: Roche — FDA application and earlier safety findings, 30 September 2026 ↗